company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2225000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7527000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9752000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9677000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,12624000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1800000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1158000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-11982000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21657000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,2000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21655000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21657000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21657000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,204220.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,25.54
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,635726.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,21.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,-800000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q1,2013-01-01,2013-03-31,2014-05-14 17:01:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,25.54
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3641000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7782000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11423000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11348000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,490000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-219000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,232000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-477000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11825000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-4000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11829000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11829000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11829000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,209307.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-75.25
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,209307.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-75.25
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q2,2013-04-01,2013-06-30,2014-08-13 17:23:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-75.25
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,158000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,158000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,158000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2142000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6284000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8426000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8268000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,351000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-44000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-182000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-577000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8845000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-38000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8883000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8883000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8883000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,228785.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-55.92
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,228785.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-55.92
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,200000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q3,2013-07-01,2013-09-30,2014-11-13 17:13:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-55.92
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,309000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,309000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,309000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,3003000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6238000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9241000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8932000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1699000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1172000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-256000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-783000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9717000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-364000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10081000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10079000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10079000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,220220.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,106.8
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,1029150.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,111.22
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,-44800000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,106.8
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,158000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,158000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,158000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4093000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7551000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11644000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11486000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,9841000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-1354000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1255000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-9940000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21426000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21426000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21426000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21426000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,11092471.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.93
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,11092471.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.93
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,11100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q1,2014-01-01,2014-03-31,2014-05-14 17:01:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.93
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4857000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8110000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,12967000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-12892000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,267000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-342000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13234000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-68000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13302000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13302000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13302000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19380934.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.69
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19380934.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.69
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19300000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q2,2014-04-01,2014-06-30,2015-08-07 16:18:52+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.69
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5300000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8600000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13900000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13825000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,228000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,81000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-147000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13972000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-5000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13977000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13977000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13977000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,23331104.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.6
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,23331104.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.6
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,23300000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q3,2014-07-01,2014-09-30,2015-11-10 17:11:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.6
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4793000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9129000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,13922000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13847000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,336000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,3748000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3616000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-204000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-14051000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-161000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-14212000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-14195000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-14195000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,19400000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.02
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,19400000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.02
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,19391523.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.02
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5996000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9254000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15250000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15175000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,165000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-15000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-180000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15355000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-47000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15402000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15402000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15402000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,23535080.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.65
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,23535080.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.65
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,23700000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q1,2015-01-01,2015-03-31,2016-05-10 16:11:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.65
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6360000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10303000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,16663000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-16588000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,279000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,138000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-141000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16729000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-76000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16805000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16805000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16805000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,23584910.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.71
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,23584910.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.71
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,23700000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 16:08:26+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.71
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5827000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13016000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,18843000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-18768000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,390000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,81000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-309000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19077000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-98000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19175000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19175000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19175000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,23755199.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.81
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,23755199.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.81
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,23700000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q3,2015-07-01,2015-09-30,2016-11-04 16:11:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.81
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,6905000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14956000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,21861000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-21786000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,356000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,154000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-202000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21988000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-106000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22094000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22118000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22118000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,24300000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.85
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,24300000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.85
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,24340466.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.85
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7455000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12364000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,19819000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-19744000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,315000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,296000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-19000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-19763000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-125000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-19888000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-19888000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-19888000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.71
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.71
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28005611.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q1,2016-01-01,2016-03-31,2017-05-09 17:12:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.71
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7018000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15192000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,1949000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,24159000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-24084000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,286000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-89000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-375000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-24459000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-143000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-24602000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-24602000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-24602000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.88
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.88
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28089731.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q2,2016-04-01,2016-06-30,2017-08-04 17:08:06+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.88
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7502000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10296000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17798000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17723000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,256000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,139000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-117000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17840000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-138000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17978000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17978000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17978000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.64
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.64
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28160458.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q3,2016-07-01,2016-09-30,2017-11-03 16:28:54+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.64
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12529000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,7151000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,26780000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26664000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,225000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,216000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-9000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26673000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-129000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26802000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26832000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26832000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.95
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.95
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28114784.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.95
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7754000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19409000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,27163000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-27088000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,193000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,251000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,58000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27030000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-126000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27156000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27156000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27156000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,28900000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.94
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,28900000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.94
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,28808195.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q1,2017-01-01,2017-03-31,2018-05-09 17:18:11+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.94
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,8609000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,18307000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,26916000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26841000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,141000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,240000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,99000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26742000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-132000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26874000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26874000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26874000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,29900000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.9
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,29900000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.9
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,29776893.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q2,2017-04-01,2017-06-30,2018-08-03 17:25:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.9
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,75000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,9148000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,21643000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,30791000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-30716000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,104000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,297000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,193000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30523000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-128000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30651000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30651000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30651000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,30300000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.01
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,30300000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.01
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,30270260.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q3,2017-07-01,2017-09-30,2018-11-02 16:06:31+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.01
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,37000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,37000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,37000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,11887000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,21002000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,2927000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35816000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-35779000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,19000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,31000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,12000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-35767000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-139000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-35906000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-35906000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-35906000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,30100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.16
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,30100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.16
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,30101125.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.16
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,193000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,193000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,193000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13616000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,22239000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35855000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-35662000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,44000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,988000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,944000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-34718000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-319000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-35037000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-35037000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-35037000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.97
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.97
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,35950593.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q1,2018-01-01,2018-03-31,2019-05-09 16:04:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.97
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,686000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,686000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,686000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12734000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,22871000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35605000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-34919000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1011000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1011000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-33908000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-172000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-34080000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-34080000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-34080000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36300000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.94
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36300000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.94
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,36123659.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q2,2018-04-01,2018-06-30,2019-08-06 16:16:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.94
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2362000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2362000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,2362000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,14155000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,21848000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,36003000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-33641000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,951000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,951000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-32690000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-144000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-32834000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-32834000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-32834000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.91
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.91
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,36272445.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q3,2018-07-01,2018-09-30,2019-11-04 16:14:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.91
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,488000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,488000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,488000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13358000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25542000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,38900000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-38412000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,933000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,933000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-37479000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3000000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-138000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-40617000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-40617000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-40617000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,36200000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.12
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,36200000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.12
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,36171582.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2018.0,Q4,2018-10-01,2018-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.12
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,278000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,278000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,278000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12910000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,23995000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,36905000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-36627000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1478000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1478000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-35149000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-155000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-35304000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-35304000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-35304000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,41500000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.85
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,41500000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.85
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,41598919.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q1,2019-01-01,2019-03-31,2020-05-07 17:23:18+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.85
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,13596000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25526000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,39122000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-39122000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1617000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1617000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-37505000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,115000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-37390000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-37390000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-37390000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43500000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.86
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43500000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.86
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43260317.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q2,2019-04-01,2019-06-30,2019-08-06 16:16:23+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.86
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,46000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,46000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,46000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,16739000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,25847000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,42586000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-42540000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,1261000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1261000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-41279000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-130000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-41409000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-41400000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-41400000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.96
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43100000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.96
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43314831.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q3,2019-07-01,2019-09-30,2019-11-04 16:14:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.96
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,89000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,89000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,89000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18766000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,27493000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,46259000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-46170000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,977000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,977000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-45193000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netincomecontinuing,othergains,"Other Gains / (Losses), net",+,credit,usd,-133000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-45326000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-45335000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-45335000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,43400000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,43400000.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,43460804.0
Revance Therapeutics Inc,RVNC,549300N33TFDZHS81H11,0001479290,2019.0,Q4,2019-10-01,2019-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.0
